Copanlisib also known as BAY 80-6946, is a potent phosphoinositide 3-kinase (PI3K) inhibitor. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents. Copanlisib was approved for the treatment of adult patients experiencing relapsed follicular lymphoma who have received at least two prior systemic therapies.
Scott WJ, Hentemann MF, Rowley RB, Bull CO, Jenkins S, Bullion AM, Johnson J, Redman A, Robbins AH, Esler W, Fracasso RP, Garrison T, Hamilton M, Michels M, Wood JE, Wilkie DP, Xiao H, Levy J, Stasik E, Liu N, Schaefer M, Brands M, Lefranc J. Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946). ChemMedChem. 2016 Jul 19;11(14):1517-30. doi: 10.1002/cmdc.201600148. Epub 2016 Jun 16. PubMed PMID: 27310202; PubMed Central PMCID: PMC5094563.
Hentemann, Martin; Wood, Jill; Scott, William; Michels, Martin; Campbell, Ann-Marie; Bullion, Ann-Marie; Rowley, R. Bruce; Redman, Aniko. Preparation of substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives for treating hyper-proliferative disorders and diseases associated with angiogenesis. WO 2008070150. (Assignee Bayer Pharmaceuticals Corporation, USA)
Xu, Xuenong; Wang, Zhe; Bao, Zhijian; Zhang, Wenjian; Su, Jian; Gu, Xinyu; Xue, Jia; Yuan, Yuhuan. Preparation method of copanlisib for treating leukemia. CN 105130998. (Assignee Suzhou Lixin Pharmaceutical Co., Ltd., Peop. Rep. China)
Peters, Jan-Georg; Stiehl, Juergen; Lovis, Kai. Synthesis of copanlisib and its dihydrochloride salt. EP 3018131. (Assignee Bayer Pharma Aktiengesellschaft, Germany)
Xu, Xuenong. Method for preparing copanlisib for treating leukemia. CN 105130997. (Assignee Suzhou Miracpharma Technology Co., Ltd., Peop. Rep. China)
Peters, Jan-Georg; Rubenbauer, Philipp; Goetz, Daniel; Grossbach, Danja; Mais, Franz-Josef; Schirmer, Heiko; Stiehl, Juergen; Lovis, Kai; Lender, Andreas; Seyfried, Martin; Zweifel, Theodor; Marty, Maurus; Weingaertner, Guenter. Synthesis of copanlisib and its dihydrochloride salt. WO 2016071435. (Assignee Bayer Pharma Aktiengesellschaft, Germany)
